{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:54:11Z","timestamp":1777578851564,"version":"3.51.4"},"reference-count":16,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Ophthalmology"],"published-print":{"date-parts":[[2004,9]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To assess the intraocular pressure lowering effect of travoprost 0.004% in patients previously treated with another topical medication, and in previously untreated patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This 12-week, open-label trial in 1590 patients was conducted at 219 sites in Switzerland. Primary open-angle glaucoma and ocular hypertension patients discontinued prior medications, and instilled 1 drop of travoprost in each affected eye at 8 pm. Untreated patients were subdivided into 2 groups: baseline IOP of \u2265 21 mmHg, and baseline IOP of \u2264 20 mmHg. Patients returned for follow-up visits at 1 and 3 months. The primary outcome was mean IOP change from baseline to follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 626 patients previously on monotherapy, and 525 previously untreated or newly-diagnosed patients, 479 and 423, respectively, completed 3 months of therapy. The mean changes from baseline at 1 month (mmHg \u00b1 SD), by prior treatment group were: beta blocker, \u22124.9 (\u00b13.6); latanoprost, \u22122.3 (\u00b1 2.8); alpha-agonist, \u22124.0 (\u00b1 3.7); dorzolamide\/timolol fixed combination, \u22123.4 (\u00b1 3.9); topical CAI, \u22124.4 (\u00b1 3.1); new IOP \u2265 21 mmHg, \u22128.6 (\u00b1 4.4); new IOP \u2264 20 mmHg, \u22124.4 (\u00b1 3.0). (All changes from baseline were statistically significant (p &lt; 0.0001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients previously treated with a single drug, travoprost decreased IOP to pressures below those achieved on prior therapy. In all groups, travoprost reduced mean IOP below 18 mmHg within 1 month of starting therapy, and control was maintained for at least 3 months. Overall, travoprost was safe and well-tolerated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/112067210401400509","type":"journal-article","created":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T00:42:51Z","timestamp":1516322571000},"page":"416-422","source":"Crossref","is-referenced-by-count":12,"title":["Intraocular Pressure Lowering Efficacy of Travoprost"],"prefix":"10.1177","volume":"14","author":[{"given":"J.T.","family":"Przydryga","sequence":"first","affiliation":[{"name":"Alcon Laboratories, Inc., Fort Worth, Texas - USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Egloff","sequence":"additional","affiliation":[{"name":"Alcon Pharmaceuticals Ltd, Huenenberg - Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Swiss Start Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2004,9,1]]},"reference":[{"key":"bibr1-112067210401400509","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.80.5.389"},{"key":"bibr2-112067210401400509","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200219060-00005"},{"key":"bibr3-112067210401400509","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(02)01010-2"},{"key":"bibr4-112067210401400509","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-200110000-00010"},{"key":"bibr5-112067210401400509","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(01)01177-1"},{"key":"bibr6-112067210401400509","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(01)01257-0"},{"key":"bibr7-112067210401400509","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(91)32340-6"},{"key":"bibr8-112067210401400509","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-200004000-00002"},{"key":"bibr9-112067210401400509","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(00)00538-9"},{"key":"bibr10-112067210401400509","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(04)90008-2"},{"key":"bibr11-112067210401400509","doi-asserted-by":"publisher","DOI":"10.1089\/108076803322472971"},{"key":"bibr12-112067210401400509","doi-asserted-by":"publisher","DOI":"10.1089\/10807680260218489"},{"key":"bibr13-112067210401400509","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.042556"},{"key":"bibr14-112067210401400509","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.02-0323"},{"key":"bibr15-112067210401400509","doi-asserted-by":"publisher","DOI":"10.1089\/108076803322473006"},{"key":"bibr16-112067210401400509","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0022-3565(24)37601-3","volume":"286","author":"Griffin B.W.","year":"1998","journal-title":"J Pharmacol Exp Ther"}],"container-title":["European Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/112067210401400509","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/112067210401400509","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:35:50Z","timestamp":1777404950000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/112067210401400509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["10.1177\/112067210401400509"],"URL":"https:\/\/doi.org\/10.1177\/112067210401400509","relation":{},"ISSN":["1120-6721","1724-6016"],"issn-type":[{"value":"1120-6721","type":"print"},{"value":"1724-6016","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}